Earnings summaries and quarterly performance for REVVITY.
Executive leadership at REVVITY.
Prahlad Singh
Detailed
President and Chief Executive Officer
CEO
AG
Anita Gonzales
Detailed
Vice President and Chief Accounting Officer
JG
Joel Goldberg
Detailed
Senior Vice President, Administration, General Counsel and Secretary
MK
Maxwell Krakowiak
Detailed
Senior Vice President and Chief Financial Officer
MV
Miriame Victor
Detailed
Senior Vice President and Chief Commercial Officer
TV
Tajinder Vohra
Detailed
Senior Vice President, Global Operations
Board of directors at REVVITY.
AM
Alexis Michas
Detailed
Non-Executive Chair
FW
Frank Witney
Detailed
Director
MK
Michael Klobuchar
Detailed
Director
MV
Michel Vounatsos
Detailed
Director
MM
Michelle McMurry-Heath
Detailed
Director
PW
Pascale Witz
Detailed
Director
PB
Peter Barrett
Detailed
Director
SC
Samuel Chapin
Detailed
Director
SV
Sophie Vandebroek
Detailed
Director
Research analysts who have asked questions during REVVITY earnings calls.
Patrick Donnelly
Citi
5 questions for RVTY
Also covers: A, AVTR, BIO +22 more
Vijay Kumar
Evercore ISI
5 questions for RVTY
Also covers: A, ABT, AVTR +21 more
Daniel Brennan
TD Cowen
4 questions for RVTY
Also covers: A, ADPT, AVTR +24 more
Luke Sergott
Barclays
4 questions for RVTY
Also covers: A, AVTR, BRKR +19 more
Michael Ryskin
Bank of America Merrill Lynch
4 questions for RVTY
Also covers: A, ALGN, AVTR +28 more
PS
Puneet Souda
Leerink Partners
4 questions for RVTY
Also covers: A, ABCL, BRKR +20 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
3 questions for RVTY
Also covers: A, ADPT, AVTR +21 more
Andrew Cooper
Raymond James
2 questions for RVTY
Also covers: AZTA, CDNA, CTKB +12 more
Catherine Schulte
Baird
2 questions for RVTY
Also covers: A, CSTL, EXAS +7 more
Dan Arias
Stifel Financial Corp.
2 questions for RVTY
Also covers: A, GH, ILMN +9 more
DA
Daniel Arias
Stifel, Nicolaus & Company, Incorporated
2 questions for RVTY
Also covers: A, AVTR, CDXS +15 more
DL
Daniel Leonard
Stifel Financial Corp.
2 questions for RVTY
Also covers: A, AVTR, BIO +15 more
DL
Dan Leonard
UBS Group AG
2 questions for RVTY
Also covers: A, AVTR, BIO +9 more
Doug Schenkel
Wolfe Research LLC
2 questions for RVTY
Also covers: A, AVTR, BRKR +15 more
Tycho Peterson
Jefferies
2 questions for RVTY
Also covers: A, AVTR, BIO +22 more
Brandon Couillard
Wells Fargo & Company
1 question for RVTY
Also covers: A, AVTR, BIO +10 more
CR
Catherine Ramsey
BTIG
1 question for RVTY
Also covers: A, EXAS, MTD
Douglas Schenkel
Wolfe Research, LLC
1 question for RVTY
Also covers: A, AVTR, BRKR +21 more
Jack Meehan
Nephron Research LLC
1 question for RVTY
Also covers: A, AVTR, BIO +17 more
Rachel Vatnsdal
JPMorgan Chase & Co.
1 question for RVTY
Also covers: A, AKYA, AVTR +11 more
Subbu Nambi
Guggenheim Securities
1 question for RVTY
Also covers: BOLD, BRKR, CARS +16 more
Recent press releases and 8-K filings for RVTY.
Revvity reports Q4 2025 results
RVTY
Earnings
Guidance Update
Share Buyback
- Revvity beat Q4 expectations with $1.70 adjusted EPS (FY $5.06, +3% YoY)
- Q4 organic revenue growth of 4% (7% diagnostics, flat life sciences); FY organic growth 3%
- Q4 adjusted operating margin 29.7%; generated $162 M free cash flow (84% conversion), FY $515 M FCF (87% conversion); net debt/EBITDA 2.7×
- Repurchased $800 M of shares in 2025 (over $1.5 B since mid-2023), reducing share count by 8.5 M
- Acquired ACD/Labs adding $20 M revenue (~75 bps growth); 2026 guidance: 2–3% organic growth, revenue $2.96–$2.99 B, adjusted EPS $5.35–$5.45, margin 28%
11 hours ago
Revvity reports Q4 2025 results and 2026 outlook
RVTY
Earnings
Guidance Update
Share Buyback
- Revenue of $772 million in Q4 2025 (+4% organic), driven by 7% diagnostic growth and flat life sciences
- Q4 adjusted EPS of $1.70, boosting full-year adjusted EPS to $5.06 alongside 3% organic full-year growth on $2.86 billion revenue
- Reiterated 2026 organic growth guidance of 2–3%, with expected revenue of $2.96 billion–$2.99 billion and adjusted EPS of $5.35–$5.45
- Repurchased >$800 million of shares in 2025 (including $168 million in Q4), reducing share count by 8.5 million; total buybacks since mid-2023 exceed $1.5 billion
- Closed ACD/Labs acquisition, expected to add ~$20 million in 2026 revenue (+75 bps growth) ; introduced AI platform Signals Synthetica to accelerate drug R&D workflows
12 hours ago
Revvity announces Q4 2025 results
RVTY
Earnings
Guidance Update
Share Buyback
- Revvity delivered Q4 revenue of $772 million (+4% organic) and adjusted EPS of $1.70, exceeding guidance; for the full year, organic growth was 3% and adjusted EPS was $5.06.
- Diagnostics segment organic growth was 7% in Q4, led by reproductive health and immunodiagnostics, while life sciences organic growth was flat.
- The company reiterated 2026 guidance of 2–3% organic growth, revenue of $2.96 billion–$2.99 billion, and adjusted EPS of $5.35–$5.45 with a 28% operating margin target.
- In 2025, Revvity repurchased over $800 million of shares (8.5 million shares), bringing total buybacks since mid-2023 to $1.5 billion (15 million shares).
- Completed the acquisition of ACD/Labs in mid-January (adding ~$20 million revenue) and launched the AI platform Signals Synthetica to enhance its software offerings.
12 hours ago
Revvity announces Q4 and full year 2025 results
RVTY
Earnings
Guidance Update
- Revvity reported Q4 2025 revenue of $772 million, up 6% year-over-year (4% organic), with GAAP EPS of $0.87 and adjusted EPS of $1.70.
- For full year 2025, revenue was $2.856 billion (up from $2.755 billion in 2024), GAAP EPS was $2.07, and adjusted EPS was $5.06.
- By segment in Q4, Life Sciences revenue was $382 million (+2%; organic flat) and Diagnostics revenue was $390 million (+10%; 7% organic).
- The company initiated 2026 guidance: total revenue of $2.96–$2.99 billion, organic growth of 2–3%, and adjusted EPS of $5.35–$5.45.
14 hours ago
Revvity announces Q4 and full year 2025 results
RVTY
Earnings
Guidance Update
- Fourth quarter revenue of $772 million (6% growth; 4% organic) with GAAP EPS of $0.87 and adjusted EPS of $1.70
- Full year 2025 revenue of $2,856 million with GAAP EPS of $2.07 and adjusted EPS of $5.06
- Q4 segment results: Life Sciences revenue of $382 million (+2%; organic flat) and Diagnostics revenue of $390 million (+10%; organic +7%)
- 2026 guidance: revenue of $2.96–$2.99 billion, organic growth of 2–3%, and adjusted EPS of $5.35–$5.45
15 hours ago
Revvity reports Q4 2025 results and issues 2026 guidance
RVTY
Earnings
Guidance Update
- Revvity delivered Q4 2025 revenue of $772 M (+6% y/y), adjusted operating margin of 29.7%, EPS of $1.70 (+20% y/y) and free cash flow of $162 M.
- For FY 2025, revenue was $2.856 B (+4% y/y), adjusted operating margin 27.1%, EPS $5.06 (+3% y/y) and free cash flow $515 M.
- Diagnostics led segment growth, with immunodiagnostics organic revenue up +7% y/y and reproductive health posting mid-single-digit growth, though margins were pressured by tariffs and FX.
- 2026 guidance calls for revenue of $2.968–2.99 B (+4–5%), adjusted operating margin ~28% and EPS of $5.35–5.45.
15 hours ago
Revvity outlines 2025 guidance and strategic priorities at JPM Healthcare Conference
RVTY
Guidance Update
Share Buyback
New Projects/Investments
- 2025 revenue guidance of ~$2.8 billion, split ~50% Life Sciences and ~50% Diagnostics, with ~85% recurring revenue
- On track for 28.0% adjusted operating margin in 2026, assuming ~18% tax rate and 2–3% organic growth driving high-single-digit EPS growth
- $1.4 billion of share repurchases since 2023, reducing share count by ~10%
- Long-term organic growth targets: 9–11% for Immunodiagnostics & Signals Software, 6–8% for Life Sciences Solutions, 2–4% for Reproductive Health
Jan 13, 2026, 5:45 PM
Revvity outlines growth strategy and targets at J.P. Morgan Healthcare Conference
RVTY
Guidance Update
Share Buyback
- Revvity today is a $2.8 billion company split roughly 50/50 between life sciences and diagnostics, with 85% of revenue from recurring consumables, services and software.
- The company launched Transcribe AI, cutting clinical lab workflow time by 40%, and reduced its own software development timelines by 10%, while partnering with Eli Lilly to embed Tune Lab models into its new Signals Synthetica AI drug-discovery platform.
- Strategic diagnostics partnerships include Genomics England’s large-scale newborn sequencing program and a Sanofi collaboration to screen for juvenile Type 1 diabetes via a four-biomarker dried-blood-spot assay.
- For 2026, Revvity targets 2%–3% organic growth, a 28% adjusted operating margin, over 85% free cash flow conversion, and has repurchased $1.4 billion of shares to reduce its share count by 10%.
Jan 13, 2026, 5:45 PM
Revvity presents at 44th J.P. Morgan Healthcare Conference
RVTY
Guidance Update
Product Launch
Share Buyback
- Revvity, a $2.8 billion life sciences and diagnostics company, generates 85% recurring revenue across consumables, assays, software and services, and employs 11,000 globally.
- Management reaffirmed 2026 guidance targeting 2–3% organic growth and a 28% adjusted operating margin, aiming for high-single-digit EPS growth under an 18% tax rate.
- Launched Transcribe AI, improving clinical lab workflow speed by 40%, and introduced the Signals Synthetica platform in partnership with Eli Lilly to accelerate AI-enabled drug discovery.
- Operational excellence efforts have boosted free cash flow conversion from 70% to over 85%, enabled $1.4 billion in share repurchases and a 10% reduction in share count.
Jan 13, 2026, 5:45 PM
Revvity outlines 2026 growth and AI strategy at JPM Healthcare Conference
RVTY
Guidance Update
Share Buyback
Product Launch
- Revvity positions as a $2.8 billion life sciences and diagnostics company, with 85% of revenue from consumables, assets, software and services equally split between segments.
- Unveiled AI initiatives—Transcribe AI reduced lab workflow time by 40%, internal AI cut software development timelines by 10%, and launched the Signals Synthetica platform in partnership with Lilly to accelerate AI-enabled drug discovery.
- Reported expansion milestones: GMP reagents projects moving 2.5× faster into bioprocessing, and U.S. autoimmune diagnostics revenue share doubled to 20% post-Euroimmun acquisition.
- Confirmed 2026 targets of 2–3% organic growth, a 28% adjusted operating margin, high single-digit EPS growth, and an 18% tax rate assumption.
- Highlighted operational excellence and capital allocation actions: $1.4 billion of share buybacks cutting share count by 10%, 10% headcount reduction, and closure of 30+ sites to shrink footprint by 10% by 2027.
Jan 13, 2026, 5:45 PM
Quarterly earnings call transcripts for REVVITY.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more